
	Search		Keep Me Updated		Tell a Friend		Add to My Favorites

PRELIMINARY SCIENTIFIC PROGRAM

Section: Clinical Development
Off Label Use: inevitable, essential or dangerous? New drugs: not always as useful as they seem? Developing End Points - Ocular Imaging
Ocular Imaging: The Next Generation	Back To Section List
Chairperson: S. Krupsky, Israel
Location Versus Fovea Mapping Improvements J. Cunha-Vaz, Portugal
Next Generation Imaging Tools S. Krupsky, Israel
Multimodal Imaging - The Benefits and Promises of Integration M.D. de Smet, The Netherlands
Precision and Reproducibility in Spectral Domain OCT J. Heier, USA

Discussion: Off Label Use - Inevitable, Essential or Dangerous?	Back To Section List
Chairperson: R. Vogel, USA
Panel: A. Lowenstein, Israel, M. De Smet, The Netherlands, D. Boyer, USA, R. Neumann, Israel
Discussion topics: Avastin has reached world wide use for AMD without being approved by any agency for that indication - Should this have happened? Should this happen again? Is Physician Directed Use morally defensible? Scientifically defensible? Are their any guiding principles that define the risk benefit assessment for the physician? For a decade or more depot triamcinolone has been used inside and around the eye- was this risky? Are the risks of intravitreal steroid too high to justify its use? Is the availability of an approved non-preserved formulation a medical advance driven by Off label Use (aka -Physician Directed Use) - or an example of commercial exploitation?

Discussion: New Drugs - Not Always as Useful as They Seem?	Back To Section List
Chairperson: R. Vogel, USA
Panel: H. Gabor, Hungary, I.S. Barequet, Israel, R.K. Brazzell, USA
If a neuroprotective drug became available - would it become an essential part of glaucoma management? If we had a drug to be used daily to prevent cataracts- would it be useful? Current antibiotic use in ophthalmology-driven by irrational fear or scientifically justified?